Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
January 10, 2025 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.,...
Recludix Pharma to Participate in Two Investor Conferences in December
November 25, 2024 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that members of Recludix’s...
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis
November 14, 2024 10:00 ET
|
Recludix Pharma, Inc.
-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the...
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
August 05, 2024 06:05 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has...
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
May 17, 2024 15:00 ET
|
Recludix Pharma, Inc.
-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader...
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
April 23, 2024 08:00 ET
|
Recludix Pharma, Inc.
Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
Recludix Pharma to Participate in Two Investor Conferences in March
February 28, 2024 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in February
February 06, 2024 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma to Present at Two Investor Conferences in November
November 09, 2023 08:00 ET
|
Recludix Pharma, Inc.
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
October 31, 2023 16:00 ET
|
Recludix Pharma, Inc.
- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis - REX-7117, as a highly selective STAT3 inhibitor, demonstrates...